IL-17 and IL-23 expression as a predictor of response to infliximab treatment in Crohn's disease
10.3760/cma.j.issn.0578-1426.2015.11.008
- VernacularTitle:白细胞介素-17和白细胞介素-23在预测英夫利西治疗克罗恩病疗效中的作用
- Author:
Xin ZHANG
;
Jia HU
;
Ting XU
;
Yan ZHANG
- Publication Type:Journal Article
- Keywords:
Crohn disease;
Interleukin-17;
Interleukin-23;
Infliximab
- From:
Chinese Journal of Internal Medicine
2015;54(11):940-944
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the value of IL-17 and IL-23 expression in response prediction of infliximab treatment in Crohn's disease (CD).Methods A total of 23 CD patients were enrolled in this study including 19 males and 4 females.Another 17 patients with colonic polyps were recruited as control group.The tissue expression of IL-17 and IL-23 in intestinal mucosa was measured by immunohistochemistry (IHC).In each specimen, IL-17 or IL-23 positive cells were counted and recorded in 10 random high power fields (HPFs).Results Infliximab was effective in sixteen patients (69.6％), while 7 patients (30.4％) did not response.The numbers of IL-17 or IL-23 positive cells were much more in responders than those in nonresponders.The median numbers of IL-17 positive cells were 26.7 (18.0, 38.6)/HPF in responders, 11.8 (7.0, 14.0)/HPF in nonresponders, 3.0 (2.0,4.0)/HPF in controls (P =0.004).The median numbers of IL-23 positive cells were 74.5(44.8, 128.6)/HPF in responders, 22.4(19.0, 38.8)/HPF in nonresponders, 3.0(2.0, 4.0)/HPF in controls (P =0.018).IL-17 or IL-23 positive mucosal cells were significantly decreased after infliximab treatment.Conclusion High expression of IL-17 and IL-23 in mucosa may predict the response to infliximab in CD patients.
